POINT RICHMOND, Calif., Feb. 7, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to present at two upcoming investor conferences.
Transcept management plans to present a general corporate overview at the:
BIO CEO and Investor Conference in New York on February 14, 2012, 9:00 a.m. ET; and
Leerink Swann Global Healthcare Conference in New York on February 15, 2012, 4:00 p.m. ET.
A live audio webcast of each presentation will be available in the investor relations section of the Transcept website at www.transcept.com. The archive of the presentation will be available there for approximately 30 days following the event.
About Transcept PharmaceuticalsTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Transcept and Purdue are parties to a collaboration agreement for the development and commercialization of Intermezzo in the United States. Transcept holds all commercialization and development rights to Intermezzo outside North America and has co-promotion rights to Intermezzo in the United States. As part of its product pipeline activities, Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For information about Intermezzo, please visit www.intermezzorx.com. For further information about Transcept, please visit www.transcept.com. Contact:Transcept Pharmaceuticals, Inc. Greg MannDirector, Corporate Communications(510) 215-3567 email@example.com SOURCE Transcept Pharmaceuticals, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV